Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Christopher A Pennell"'
Autor:
Travis S Young, Mark J Osborn, Bruce R Blazar, Michael Jensen, Christopher A Pennell, Heather Campbell, Sophie Viaud, Meghan D Storlie, Sara Bolivar-Wagers, Yosef Refaeli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be r
Externí odkaz:
https://doaj.org/article/ed50d02bfc084d5ea6b825836143728f
Autor:
Stephanie C. Papillon, Christopher P. Pennell, Sahal A. Master, Evan M. Turner, L. Grier Arthur, Harsh Grewal, Stephen C. Aronoff
Publikováno v:
Journal of Pediatric Surgery. 58:1200-1205
Autor:
Pamela C. Rosato, Sathi Wijeyesinghe, J. Michael Stolley, Christine E. Nelson, Rachel L. Davis, Luke S. Manlove, Christopher A. Pennell, Bruce R. Blazar, Clark C. Chen, Melissa A. Geller, Vaiva Vezys, David Masopust
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
The immunosuppressive tumor environment and the lack of functional anti-tumor immunity are major limiting factors in immunotherapy. Here the authors show that human and mouse tumors are infiltrated by virus-specific memory T cells, which can be harne
Externí odkaz:
https://doaj.org/article/5f068cea4ece4349a43cb5cd50da3600
Autor:
Kiara Ellis, Christopher A. Pennell
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Immunotherapy is now mainstream. Advertisements are ubiquitous in print and visual media for immune based-therapies for various conditions and diseases. Smaller companies that develop novel immunotherapies are often quickly acquired by larger compani
Externí odkaz:
https://doaj.org/article/5742e224992840d2bf89c5a9607df761
Autor:
Christopher A Pennell, Heather Campbell, Meghan D Storlie, Sara Bolivar-Wagers, Mark J Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S Young, Bruce R Blazar
Publikováno v:
Journal for immunotherapy of cancer. 10(12)
Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be r
Autor:
Sara Bolivar-Wagers, Michael L. Loschi, Sujeong Jin, Govindarajan Thangavelu, Jemma H. Larson, Cameron S. McDonald-Hyman, Ethan A. Aguilar, Asim Saha, Brent H. Koehn, Mehrdad Hefazi, Mark J. Osborn, Michael C. Jensen, John E. Wagner, Christopher A. Pennell, Bruce R. Blazar
Publikováno v:
JCI Insight. 7
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) efficacy is complicated by graft-versus-host disease (GVHD), a leading cause of morbidity and mortality. Regulatory T cells (Tregs) have shown efficacy in preventing GVHD. However, high T
Autor:
Luke S. Manlove, J. Michael Stolley, Christine E. Nelson, Vaiva Vezys, Pamela C. Rosato, Bruce R. Blazar, David Masopust, Christopher A. Pennell, Rachel L. Davis, Melissa A. Geller, Clark C. Chen, Sathi Wijeyesinghe
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
Nature Communications
Nature Communications
The immunosuppressive tumor microenvironment limits the success of current immunotherapies. The host retains memory T cells specific for previous infections throughout the entire body that are capable of executing potent and immediate immunostimulato
Autor:
Michael R. Olin, Clark C. Chen, Christopher L. Moertel, Elisabet Ampudia-Mesias, Aaron L. Sarver, G. Elizabeth Pluhar, Christopher A. Pennell, Matthew A. Hunt
Publikováno v:
Cancers, Vol 11, Iss 2, p 137 (2019)
Cancers
Volume 11
Issue 2
Cancers
Volume 11
Issue 2
Recent advances in immunotherapy have included inhibition of immune checkpoint proteins in the tumor microenvironment and tumor lysate-based vaccination strategies. We combined these approaches in pet dogs with high-grade glioma. Administration of a
Autor:
Michael Olin, Elisabet Ampudia-Mesias, Christopher A Pennell, Zhengming Xiong, Susan K Rathe, David A Largaespada, Christopher L Moertel, G Elizabeth Pluhar
Numerous ongoing clinical trials targeting immune checkpoints have failed to enhance survival in patients with CNS tumors. We are targeting a unique checkpoint, CD200, which controls the immune system through paired inhibitory and activation receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1712fe6312885462b22462a1d37bba51
https://europepmc.org/articles/PMC6216804/
https://europepmc.org/articles/PMC6216804/
Autor:
Yosef Refaeli, Jessie L. Barnum, Angela Panoskaltsis-Mortari, Jeffrey S. Miller, Heather Campbell, Zhengming Xiong, Govindarajan Thangavelu, Scott N. Furlan, Mark J. Osborn, Megan J. Riddle, Michael C. Jensen, Christopher A. Pennell, Cameron McDonald-Hyman, Bruce R. Blazar, Leslie S. Kean, Meghan D. Storlie, Michael Loschi, Jakub Tolar
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 26(6)
The clinical success of chimeric antigen receptor (CAR) T cell therapy for CD19(+) B cell malignancies can be limited by acute toxicities and immunoglobulin replacement needs due to B cell aplasia from persistent CAR T cells. Life-threatening complic